Methotrexate-induced pulmonary lymphoma.

Methotrexate has proven to be effective in treating rheumatoid arthritis (RA), and is believed to be nononcogenic in the low weekly dose typically employed in the patients with RA. We report, however, a patient with RA in whom a rapidly enlarging diffuse large B-cell lymphoma developed in the left upper lung after weekly treatment with methotrexate for 5 years. The patient had a positive serum IgG for Epstein-Barr virus but a negative in situ hybridization of the resected specimen. Methotrexate therapy was discontinued, and the patient elected for clinical observation instead of chemotherapy or radiation therapy. There has been no clinically detectable recurrence of the lymphoproliferative disorder for 2 years. We believe that methotrexate has an oncogenic potential even in low weekly dosing in a subset of patients with RA and latent Epstein-Barr virus infection. The strongest causal link is demonstrated by the persistent tumor remission after stopping treatment with methotrexate.
AuthorsCelso T Ebeo, Mirle R Girish, Ryland P Byrd, Thomas M Roy, Jay B Mehta
JournalChest (Chest) Vol. 123 Issue 6 Pg. 2150-3 (Jun 2003) ISSN: 0012-3692 [Print] United States
PMID12796204 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antirheumatic Agents
  • Carcinogens
  • Methotrexate
  • Antirheumatic Agents (adverse effects)
  • Arthritis, Rheumatoid (drug therapy)
  • Carcinogens (adverse effects)
  • Humans
  • Lung Neoplasms (chemically induced)
  • Lymphoma, B-Cell (chemically induced)
  • Male
  • Methotrexate (adverse effects)
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: